Company News Environmental
What are bioprocess containers?
Used daily across the scientific research and pharmaceutical industries, biocontainers have an extensive range of uses that help to streamline […]
Nov 05th, 2024
MilliporeSigma has unveiled survey results of 250 global biopharmaceutical executives on how their companies will manage new risks created by the fast-changing biopharmaceutical landscape.
The survey, which was sponsored by MilliporeSigma, was conducted by leading research group the Economist Intelligence Unit (EIU).
“In response to the uncertainty and disruption facing the biopharmaceutical industry, MilliporeSigma has moved beyond old risk-management models and has adopted and is applying new strategies at the earliest stages of development and seeing them through to commercialisation,” explained Udit Batra, Member, Executive Board, Merck KGaA, Darmstadt, Germany and CEO, MilliporeSigma.
MilliporeSigma revealed the findings at the BIO International Convention, in San Francisco, California on June 8th, 2016.
Key study highlights include:
To download the report and access additional content on the changing nature of biopharma, visit www.gobeyondbiopharma.com